Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …

CD20 monoclonal antibody (mAb) immunotherapy is effective for lymphoma and
autoimmune disease. In a mouse model of immunotherapy using mouse anti–mouse CD20 …

Despite the demonstrated clinical efficacy of CD20 monoclonal antibody (mAb) for
lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and …

CD19, a B cell–restricted receptor critical for B-cell development, is expressed in most B-cell
malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574, has enhanced Fcγ …

Current therapies for non-Hodgkin lymphoma commonly include CD20 mAb to deplete
tumor cells. However, the response is not durable in a substantial proportion of patients …

Although anti-CD20 immunotherapy effectively treats human lymphoma and autoimmune
disease, the in vivo effect of immunotherapy on tissue B cells and their subsets is generally …

B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat
rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy …

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …

CD20 antibody depletion of B lymphocytes effectively ameliorates multiple T cell-mediated
autoimmune diseases through mechanisms that remain unclear. To address this, a mouse …

CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …